A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Exclusion Criteria

• •Has hypersensitivity or other contraindication to any component of the study interventions
• •Has evidence of acute or chronic hepatitis B infection
• •Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
• •Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time
• •Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration
• •Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1